Background & aim: Bulk RNA-sequencing has limited cellular-level insight into metabolic-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC) by masking rare and tumor-relevant populations. Here, we used single-cell transcriptomics to characterize liver cell-specific transcriptomic changes in the GAN…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunctionassociated steatohepatitis (MASH). Efruxifermin (EFX) is a long acting FGF21 analogue currently in phase 3…
Background & aim: The long-acting glucagon-like peptide-1 (GLP1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…
Background & aim: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). Importantly, semaglutide was recently approved as the first GLP-1-based treatment for people with MASH with moderate-to-severe fibrosis. Translational models that recapitulate…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX) is a long-acting FGF21 analogue currently inphase 3 clinical development for pre-cirrhotic…
Background & aim: NLT-101 is a first-in-class compound that functions by proximity engagement with a target in the nuclear envelope that mediates its activity. NLT-101 is in preclinical development for metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis driven indications. The present…
Background & aim: The glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist tirzepatide is currently approved for the treatment of obesity and type 2 diabetes. In a recent phase 2b trial (SYNERGY-NASH) in patients with metabolic-dysfunction…
Background & aim: The long-acting glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved for the treatment of type 2 diabetes and obesity. Recently, semaglutide has been reported to improve liver histopathological outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis…
Background & aim: OPK-88006 is a novel peptide-based, long-acting glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist in current preclinical development for metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). The present study aimed to compare the therapeutic profile…
